Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA margin is N/A as of Tuesday, October 6, 2026.
EBITDA MARGIN
N/A
Market Cap
$13.37M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$13.48M
EBITDA Margin
-839.37%
TTM Avg
-1027.77%
3Y Avg
-3215.79%
5Y Avg
-3215.79%
Market Cap
$13.99M
EBITDA Margin
-988.11%
TTM Avg
-1002.20%
3Y Avg
-1043.90%
5Y Avg
-1194.77%
Market Cap
$12.62M
EBITDA Margin
-34.02%
TTM Avg
-37.67%
3Y Avg
-64.98%
5Y Avg
-56.41%
Market Cap
$14.11M
EBITDA Margin
-23.39%
TTM Avg
-215.41%
3Y Avg
-426.39%
5Y Avg
-612.06%
Market Cap
$14.11M
EBITDA Margin
-855.47%
TTM Avg
-475.86%
3Y Avg
-335.10%
5Y Avg
-307.83%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| IN8bio, Inc. (INAB) | $13.33M | N/A | N/A | N/A | N/A |
| Citius Pharmaceuticals, Inc. (CTXR)vs › | $13.37M | N/A | N/A | N/A | N/A |
| Optimi Health Corp. (OPTH)vs › | $13.48M | -839.37% | -1027.77% | -3215.79% | -3215.79% |
| Sintx Technologies, Inc. (SINT)vs › | $13.99M | -988.11% | -1002.20% | -1043.90% | -1194.77% |
| Obsidian Therapeutics Inc. (OBX)vs › | $13.81M | N/A | N/A | N/A | N/A |
| Passage Bio, Inc. (PASG)vs › | $12.77M | N/A | N/A | N/A | N/A |
| Cytosorbents Corporation (CTSO)vs › | $12.62M | -34.02% | -37.67% | -64.98% | -56.41% |
| Pulsenmore Ltd. Ordinary Shares (PLSM)vs › | $14.11M | -23.39% | -215.41% | -426.39% | -612.06% |
| Vyome Holdings, Inc. (HIND)vs › | $14.11M | -855.47% | -475.86% | -335.10% | -307.83% |
| Lantern Pharma Inc. (LTRN)vs › | $12.25M | N/A | N/A | N/A | N/A |
Gross Margin
0.0%
EBITDA Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
